Laboratorios Farmaceuticos Rovi, S.A.
LABFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.98 | -1.03 | 0.36 | 0.15 |
| FCF Yield | 1.70% | 2.32% | 7.30% | 3.24% |
| EV / EBITDA | 22.91 | 10.68 | 9.21 | 16.91 |
| Quality | ||||
| ROIC | 19.78% | 27.75% | 33.14% | 27.71% |
| Gross Margin | 61.24% | 58.27% | 62.67% | 58.56% |
| Cash Conversion Ratio | 0.78 | 0.51 | 0.92 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.25% | 8.54% | 24.87% | 19.38% |
| Free Cash Flow Growth | 31.00% | -68.82% | 71.62% | 1,410.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.44 | 0.17 | -0.19 | -0.13 |
| Interest Coverage | 73.80 | 232.34 | 303.00 | 199.94 |
| Efficiency | ||||
| Inventory Turnover | 0.90 | 1.02 | 0.98 | 1.10 |
| Cash Conversion Cycle | 368.61 | 297.71 | 294.00 | 271.35 |